139 lines
36 KiB
Text
139 lines
36 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK594406">
|
|
<meta name="ncbi_domain" content="livertox">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK594406/?report=reader">
|
|
<meta name="ncbi_pagename" content="Tebentafusp - LiverTox - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Tebentafusp - LiverTox - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/livertox/Tazemetostat/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/livertox/Teclistamab/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/livertox/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]">
|
|
<meta name="citation_title" content="Tebentafusp">
|
|
<meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases">
|
|
<meta name="citation_date" content="2023/07/30">
|
|
<meta name="citation_pmid" content="37643277">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK594406/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Tebentafusp">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases">
|
|
<meta name="DC.Date" content="2023/07/30">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK594406/">
|
|
<meta name="description" content="Tebentafusp is a recombinant bispecific fusion protein that binds both the gp100 peptide expressed in HLA-A*02:01 on melanoma cells and the CD3 T cell engager. It is used to treat metastatic or unresectable uveal melanoma. Tebentafusp is associated with frequent elevations in serum ALT, AST and bilirubin during therapy, usually in association with cytokine release syndrome that can lead to interruption or early discontinuation of therapy, but instances of clinically apparent liver injury with jaundice independent of cytokine release syndrome have not been reported.">
|
|
<meta name="og:title" content="Tebentafusp">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="Tebentafusp is a recombinant bispecific fusion protein that binds both the gp100 peptide expressed in HLA-A*02:01 on melanoma cells and the CD3 T cell engager. It is used to treat metastatic or unresectable uveal melanoma. Tebentafusp is associated with frequent elevations in serum ALT, AST and bilirubin during therapy, usually in association with cytokine release syndrome that can lead to interruption or early discontinuation of therapy, but instances of clinically apparent liver injury with jaundice independent of cytokine release syndrome have not been reported.">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK594406/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/livertox/Tebentafusp/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK594406/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8D8DA57D7F4D510000000000790061.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK594406/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/livertox/Tazemetostat/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">Tebentafusp</div><div class="j">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</div></div><div class="tail"><a href="/books/n/livertox/Teclistamab/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK594406/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK594406/&text=Tebentafusp"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/livertox/?report=reader">Title Information</a><a href="/books/n/livertox/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK594406/?report=classic">Switch to classic view</a><a href="/books/NBK594406/pdf/Bookshelf_NBK594406.pdf">PDF (84K)</a><a href="/books/NBK594406/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK594406%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8D8DA57D7F4D510000000000790061.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK594406_"><span class="title" itemprop="name">Tebentafusp</span></h1><p class="fm-aai"><a href="#_NBK594406_pubdet_">Publication Details</a></p></div></div><div class="body-content whole_rhythm" itemprop="text"><div id="Tebentafusp.OVERVIEW"><h2 id="_Tebentafusp_OVERVIEW_">OVERVIEW</h2><div id="Tebentafusp.Introduction"><h3>Introduction</h3><p>Tebentafusp is a recombinant bispecific fusion protein that binds both the gp100 peptide expressed in HLA-A*02:01 on melanoma cells and the CD3 T cell engager. It is used to treat metastatic or unresectable uveal melanoma. Tebentafusp is associated with frequent elevations in serum ALT, AST and bilirubin during therapy, usually in association with cytokine release syndrome that can lead to interruption or early discontinuation of therapy, but instances of clinically apparent liver injury with jaundice independent of cytokine release syndrome have not been reported.</p></div><div id="Tebentafusp.Background"><h3>Background</h3><p>Tebentafusp (te ben’ ta fusp) is a recombinant bispecific fusion protein that binds both the gp100 peptide expressed in HLA-A*02:01 on melanoma cells and the CD3 T cell engager. HLA-A*02:01 is the most common HLA complex in humans found in 50% of persons with European American ancestry. Thus, tebentafusp activates cytotoxic CD3 T cells in the presence of melanoma expressed gp100 peptide causing an immune lysis of the melanoma cells. Tebentafusp was found to be effective in animal models of human uveal melanoma, a particularly resistant and rapidly fatal form of the malignancy. In a randomized controlled trial in patients with metastatic uveal melanoma, tebentafusp was associated with an improvement in one year survival compared to standard melanoma therapies (73% vs 59%). Tebentafusp was approved in the United States in 2022 as therapy of metastatic or unresectable uveal melanoma in adults with HLA-A*02:01. It remains under evaluation in other forms of advanced melanoma. Tebentafusp is available in solution for injection in single dose vials of 100 mcg in 0.5 mL (200 mcg/mL) under the brand name Kimmtrak. The recommended dose is once weekly intravenous infusions of 20 mcg on day 1, 30 mcg on day 8, and 68 mcg on day 15 and once weekly thereafter. Tebentafusp has a high rate of adverse events, most commonly a mild-to-moderate cytokine release syndrome caused by the generalized activation of CD3 T cells. Symptoms include fever, chills, fatigue, rash, pruritus, dry skin, abdominal pain, nausea, vomiting, headache, hypotension, edema, dyspnea. Laboratory abnormalities include lymphopenia and anemia, as well as increase in glucose, creatinine, serum ALT, AST and bilirubin levels. Potentially severe adverse events include severe cytokine release syndrome and embryo-fetal toxicity.</p></div><div id="Tebentafusp.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>In prelicensure controlled trials, serum ALT or AST elevations occurred in 65% of tebentafusp treated subjects arising in association with cytokine release syndrome that typically occurs during the first few months of therapy. Most of these elevations were mild-to-moderate in severity and resolved rapidly despite continuation of treatment. ALT elevations arose in 52% of tebentafusp treated patients and were above 5 times the ULN in 9%, compared to the comparator arm receiving standard therapy for melanoma in whom ALT elevations arose in 29% and were above 5 times ULN in 2%. Bilirubin elevations were also more frequent (27% vs 14% in comparator arms). ALT or AST elevations led to temporary interruption of therapy in 5% of patients but to permanent discontinuation in only 0.4%. Most liver enzyme and bilirubin elevations occurred in the context of cytokine release syndrome. In preregistration clinical trials and subsequently with its more widespread use, tebentafusp has not been linked to instances of clinically apparent liver injury independent of the cytokine release syndrome.</p><p>Likelihood score: E* (unproven but suspected rare cause of clinically apparent liver injury).</p></div><div id="Tebentafusp.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>Tebentafusp is a recombinant human protein and as such is unlikely to be intrinsically hepatotoxic. Because tebentafusp induces a strong CD3 T cell response to the tumor antigen, it causes release of proinflammatory cytokines that can induce transient liver injury, the recombinant fusion protein being a cause of transient “indirect” drug induced liver injury. Because melanoma is also frequently found in liver, the lysis of liver melanoma cells and local release of inflammatory cytokines may particularly induce evidence liver injury and dysfunction.</p></div><div id="Tebentafusp.Outcome_and_Management"><h3>Outcome and Management</h3><p>Tebentafusp has been linked to mild-to-moderate serum enzyme elevations during therapy. Discontinuation for serum enzyme elevations is usually not necessary, but should be done if the elevations are persistently above 5 times ULN. There is no information on cross sensitivity to liver injury between tebentafusp and other growth factors or therapies for melanoma.</p><p>Drug Class: <a href="/books/n/livertox/AntineoplasticAgents/?report=reader">Antineoplastic Agents</a></p></div></div><div id="Tebentafusp.PRODUCT_INFORMATION"><h2 id="_Tebentafusp_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figTebentafuspTc"><a href="/books/NBK594406/table/Tebentafusp.Tc/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figTebentafuspTc" rid-ob="figobTebentafuspTc"><img class="small-thumb" src="/books/NBK594406/table/Tebentafusp.Tc/?report=thumb" src-large="/books/NBK594406/table/Tebentafusp.Tc/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="Tebentafusp.Tc"><a href="/books/NBK594406/table/Tebentafusp.Tc/?report=objectonly" target="object" rid-ob="figobTebentafuspTc">Table</a></h4><p class="float-caption no_bottom_margin"><i>REPRESENTATIVE TRADE NAMES</i> Tebentafusp – Kimmtrak®</p></div></div></div><div id="Tebentafusp.CHEMICAL_FORMULA_AND_STRUCTU"><h2 id="_Tebentafusp_CHEMICAL_FORMULA_AND_STRUCTU_">CHEMICAL FORMULA AND STRUCTURE</h2><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figTebentafuspTd"><a href="/books/NBK594406/table/Tebentafusp.Td/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figTebentafuspTd" rid-ob="figobTebentafuspTd"><img class="small-thumb" src="/books/NBK594406/table/Tebentafusp.Td/?report=thumb" src-large="/books/NBK594406/table/Tebentafusp.Td/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="Tebentafusp.Td"><a href="/books/NBK594406/table/Tebentafusp.Td/?report=objectonly" target="object" rid-ob="figobTebentafuspTd">Table</a></h4></div></div></div><div id="Tebentafusp.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Tebentafusp_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 30 July 2023</p><p>Abbreviations used: CRS, cytokine release syndrome; iv, intravenous; TCR, T cell receptor.</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Tebentafusp.REF.fda">FDA. <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761228Orig1s000MultidisciplineR.pdf" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">https://www<wbr style="display:inline-block"></wbr>​.accessdata<wbr style="display:inline-block"></wbr>​.fda.gov/drugsatfda_docs<wbr style="display:inline-block"></wbr>​/nda/2022/761228Orig1s000MultidisciplineR.pdf</a><div><i>(FDA website including product label and multidiscipline review of data submitted in support of the approval of tebentafusp, mentions that ALT and AST elevations arose in two-thirds of treated patients, and qualified as being serious adverse events in 11 [4.4%], resulting in withholding therapy in 13 [15%] and permanent discontinuation in one patient [0.4%], but there were no liver related deaths).</i></div></div></li><li><div class="bk_ref" id="Tebentafusp.REF.middleton.2020.5869">Middleton
|
|
MR, McAlpine
|
|
C, Woodcock
|
|
VK, Corrie
|
|
P, Infante
|
|
JR, Steven
|
|
NM, Evans
|
|
TRJ, et al.
|
|
Tebentafusp, a TCR/Anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma.
|
|
Clin Cancer Res.
|
|
2020;26:5869-5878. [<a href="/pmc/articles/PMC9210997/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9210997</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32816891" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32816891</span></a>]<div><i>(Among 84 patients with advanced metastatic melanoma [19 with uveal melanoma] who were treated with various dose regimens of tebentafusp intravenously [iv], the one year survival rate was 60% while the overall response rate was only 9%, and 60% of patients had the cytokine release syndrome [CRS] with levels of cytokines highest for CXCL11, CXCL10, IL2, IL6 and IL10, and best survival achieved in patients with the highest CXCL10 levels and appearance of rash within 21 days).</i></div></div></li><li><div class="bk_ref" id="Tebentafusp.REF.nathan.2021.1196">Nathan
|
|
P, Hassel
|
|
JC, Rutkowski
|
|
P, Baurain
|
|
JF, Butler
|
|
MO, Schlaak
|
|
M, Sullivan
|
|
RJ, et al.; IMCgp100-202 investigators. Overall survival benefit with tebentafusp in metastatic uveal melanoma.
|
|
N Engl J Med.
|
|
2021;385:1196-1206. [<a href="https://pubmed.ncbi.nlm.nih.gov/34551229" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34551229</span></a>]<div><i>(Among 378 treatment-naive, HLA-A*02:01-positive patients with metastatic uveal melanoma treated with weekly iv tebentafusp or with preferred standard therapies, overall 1-year survival rates were 73% vs 59% and the most frequent tebentafusp related adverse event was CRS [89% vs 3%], and ALT elevations arose in 18% vs 7% and bilirubin in 9% vs 2%, usually during the first 4 weeks of therapy).</i></div></div></li><li><div class="bk_ref" id="Tebentafusp.REF.carvajal.2022.1939">Carvajal
|
|
RD, Nathan
|
|
P, Sacco
|
|
JJ, Orloff
|
|
M, Hernandez-Aya
|
|
LF, Yang
|
|
J, Luke
|
|
JJ, et al.
|
|
Phase I study of safety, tolerability, and efficacy of tebentafusp using a step-up dosing regimen and expansion in patients with metastatic uveal melanoma.
|
|
J Clin Oncol.
|
|
2022;40:1939-1948. [<a href="/pmc/articles/PMC9177239/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9177239</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35254876" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35254876</span></a>]<div><i>(Among 42 adults with refractory metastatic uveal melanoma and HLA-A*02:01 treated with escalating doses of tebentafusp [20, 30, 54 and 68 mcg], the 68 mcg dose was chosen for future study, and the overall response rate was 12%, 1-year survival rate 67%, and most frequent adverse events were fever [91%], rash [83%], pruritus [83%], nausea [74%] and fatigue [71%]; while ALT elevations arose in 5%, AST in 7%, and bilirubin in 5%, there were no discontinuations for liver test abnormalities and no treatment-related deaths).</i></div></div></li><li><div class="bk_ref" id="Tebentafusp.REF.dhillon.2022.703">Dhillon
|
|
S.
|
|
Tebentafusp: first approval.
|
|
Drugs.
|
|
2022;82:703-710. [<a href="https://pubmed.ncbi.nlm.nih.gov/35364798" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35364798</span></a>]<div><i>(Review of the mechanism of action, history of development, pharmacokinetics, clinical efficacy, and safety shortly after its approval as therapy of uveal melanoma in the US, mentions that CRS developed in 89% of patients [defined as presence of fever, hypotension and hypoxia] but was usually mild-to-moderate in severity with grade 3 CRS in only 1% of subjects and no cases of death from CRS, and while ALT and AST elevations were frequent [65-71%], they were usually mild-to-moderate and, if more severe [in 4-16%], were often self-limited even with continuing therapy).</i></div></div></li><li><div class="bk_ref" id="Tebentafusp.REF.carvajal.2022.2364">Carvajal
|
|
RD, Butler
|
|
MO, Shoushtari
|
|
AN, Hassel
|
|
JC, Ikeguchi
|
|
A, Hernandez-Aya
|
|
L, Nathan
|
|
P, et al.
|
|
Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial.
|
|
Nat Med.
|
|
2022;28:2364-2373. [<a href="/pmc/articles/PMC9671803/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9671803</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36229663" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 36229663</span></a>]<div><i>(Among 127 patients with refractory, metastatic uveal melanoma and HLA A*02:01 treated with tebentafusp, the primary response rate was only 5% but the one year median survival rate was 62%, higher than the established historical rate of only 37% ).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK594406_pubdet_">Publication Details</h2><h3>Publication History</h3><p class="small">Last Update: <span itemprop="dateModified">July 30, 2023</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div></div><h3>Publisher</h3><p><a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>, Bethesda (MD)</p><h3>NLM Citation</h3><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Tebentafusp. [Updated 2023 Jul 30].<span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"><a href="/books/n/livertox/Tazemetostat/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/livertox/Teclistamab/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article><article data-type="table-wrap" id="figobTebentafuspTc"><div id="Tebentafusp.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK594406/table/Tebentafusp.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Tebentafusp.Tc_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><br /><p><b>REPRESENTATIVE TRADE NAMES</b></p>
|
|
<p>Tebentafusp – Kimmtrak®</p>
|
|
<p><b>DRUG CLASS</b></p>
|
|
<p>Antineoplastic Agents</p>
|
|
<p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Tebentafusp" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">COMPLETE LABELING</a></p>
|
|
<p>Product labeling at DailyMed, National Library of Medicine, NIH</p></td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobTebentafuspTd"><div id="Tebentafusp.Td" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK594406/table/Tebentafusp.Td/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Tebentafusp.Td_lrgtbl__"><table><thead><tr><th id="hd_h_Tebentafusp.Td_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_h_Tebentafusp.Td_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY NO.</th><th id="hd_h_Tebentafusp.Td_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Tebentafusp.Td_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Tebentafusp.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tebentafusp</td><td headers="hd_h_Tebentafusp.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1874157-95-5</td><td headers="hd_h_Tebentafusp.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Recombinant Protein</td><td headers="hd_h_Tebentafusp.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not Available</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal106 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|